INT24615

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 1989
Last Reported 1998
Negated 1
Speculated 0
Reported most in Abstract
Documents 3
Total Number 3
Disease Relevance 0.33
Pain Relevance 1.30

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
spinal 2
pcp (Mus musculus)
Pain Link Frequency Relevance Heat
dopamine receptor 3 99.76 Very High Very High Very High
cocaine 2 99.28 Very High Very High Very High
withdrawal 1 98.86 Very High Very High Very High
Opioid 3 98.64 Very High Very High Very High
substance P 4 98.28 Very High Very High Very High
agonist 5 97.88 Very High Very High Very High
nMDA receptor antagonist 1 97.70 Very High Very High Very High
antinociception 1 97.08 Very High Very High Very High
antagonist 1 83.56 Quite High
nMDA receptor 3 75.00 Quite High
Disease Link Frequency Relevance Heat
Substance Withdrawal Syndrome 1 99.04 Very High Very High Very High
Nociception 4 98.84 Very High Very High Very High
Drug Dependence 1 49.04 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
However, similar treatment with haloperidol (4 mg.kg-1.day-1) induced: 1) complete elimination of the binding to sigma h sites, 2) up-regulation of D-2 dopamine receptors, and 3) no change in sigma p and PCP receptor binding after 14 or 21 days of treatment.
Neg (no) Regulation (change) of PCP receptor Binding (binding) of associated with dopamine receptor
1) Confidence 0.37 Published 1989 Journal FASEB J. Section Abstract Doc Link 2541039 Disease Relevance 0 Pain Relevance 0.26
Our results confirm the existence of NMDA/PCP receptor complexes in spinal systems mediating nociception and suggest agonists may induce antinociception by interacting with spinal PCP receptors.
Regulation (existence) of PCP Binding (complexes) of in spinal associated with nociception, antinociception and agonist
2) Confidence 0.05 Published 1989 Journal Eur. J. Pharmacol. Section Abstract Doc Link 2468511 Disease Relevance 0.23 Pain Relevance 0.61
Since NMDA receptor antagonists (e.g., MK-801) are thought to attenuate opioid withdrawal symptoms and cocaine sensitization, it is possible that binding of ibogaine to the PCP sites contributes to its potential 'endabuse' properties.
Regulation (contributes) of PCP Binding (binding) of associated with nmda receptor antagonist, withdrawal, opioid and cocaine
3) Confidence 0.04 Published 1998 Journal Ann. N. Y. Acad. Sci. Section Abstract Doc Link 9668682 Disease Relevance 0.10 Pain Relevance 0.42

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox